What is the recommended primary‑care surveillance schedule and assessments for a patient after completing cancer treatment?

Post-Cancer Treatment Primary Care Monitoring

Primary care surveillance after cancer treatment should follow a risk-stratified schedule with history and physical examination every 3-6 months for the first 3 years, every 6-12 months for years 4-5, and annually thereafter, combined with cancer-specific imaging (mammography for breast cancer annually, chest CT every 6 months for 2 years then annually for lung cancer) while avoiding routine laboratory tests and non-indicated imaging studies.

General Surveillance Framework

The core surveillance strategy across cancer types follows a consistent pattern that intensifies early post-treatment when recurrence risk is highest, then gradually decreases 1, 2, 1:

Visit Schedule by Time Period

Years 1-3 post-treatment:

• History and physical examination every 3-6 months
• Focus on cancer-specific symptoms and treatment-related complications
• This is when 60-70% of recurrences typically occur

Years 4-5 post-treatment:

• Visits every 6-12 months
• Continue symptom surveillance
• Transition planning to primary care may begin after year 1 for early-stage disease 3

Beyond 5 years:

• Annual visits
• Shift focus to second primary cancers and late treatment effects
• Primary care physician can assume primary responsibility with oncology consultation as needed

Cancer-Specific Surveillance Protocols

Breast Cancer 1, 3

Recommended surveillance:

• Annual mammography of treated breast (or both breasts if breast-conserving therapy)
• First post-radiation mammogram at 6 months, then annually
• Physical examination including breast and lymph node assessment at each visit
• Patient education on self-examination and symptoms of recurrence

NOT recommended:

• Routine tumor markers (CA 15-3, CA 27.29, CEA)
• Routine imaging (chest X-ray, bone scans, liver ultrasound, CT, PET scans)
• Routine blood tests (CBC, chemistry panels)
• Breast MRI unless patient meets high-risk criteria for hereditary syndromes

Head and Neck Cancer 4, 2

Recommended surveillance:

• More intensive early follow-up: every 1-3 months in year 1, every 2-6 months in year 2, every 4-8 months in years 3-5
• Direct nasopharyngolaryngoscopy by otolaryngologist or head/neck specialist
• Baseline imaging within 6 months post-treatment for T3/T4 or N2/N3 disease
• Annual lung cancer screening with low-dose CT for high-risk patients based on smoking history

Key consideration: Head and neck cancer requires continued specialist involvement for direct visualization of the upper aerodigestive tract, not just primary care follow-up.

Colorectal Cancer 5

Years 1-2:

• History and physical every 3-6 months
• CEA every 3-6 months
• Chest/abdominal/pelvic CT every 12 months (stages I-III); every 3-6 months (stage IV with no evidence of disease)
• Colonoscopy at 1 year; if advanced adenoma found, repeat at year 2

Years 3-5:

• History and physical every 6 months
• CEA every 6 months for T2 or greater tumors
• CT imaging every 12 months for high-risk stage I-III and stage III disease
• Colonoscopy at year 4 if no advanced adenoma, then every 5 years

Beyond 5 years:

• Annual history and physical
• CEA monitoring NOT recommended
• CT imaging NOT recommended
• Colonoscopy every 5 years starting 8 years after resection

Lung Cancer 6

Recommended surveillance:

• Chest CT every 6 months for 2 years, then annually for detection of new primary lung cancers
• Brain MRI every 3 months for first year, then every 6 months in second year for SCLC only (NOT for NSCLC)

NOT recommended:

• PET/CT for routine surveillance
• Circulating biomarkers for recurrence detection

Gynecologic Cancers 7

Endometrial, ovarian, cervical cancers:

• History focusing on symptoms (bleeding, pain, bowel/bladder changes) and physical examination including pelvic exam are most effective
• Routine cytology and imaging have NOT shown improved detection of curable recurrences
• Most recurrences detected by patient-reported symptoms or physical examination findings

What NOT to Do (Critical Pitfalls)

Across all cancer types, these practices are consistently NOT recommended 1, 5, 1, 3:

• Routine laboratory tests (CBC, liver function tests, chemistry panels) in asymptomatic patients
• Routine tumor markers without clinical indication
• Routine cross-sectional imaging (CT, MRI, PET) beyond cancer-specific protocols
• PET/CT scans for surveillance (as opposed to diagnostic workup)

The evidence shows these tests increase costs, patient anxiety, and false-positive workups without improving survival outcomes.

Patient Education Components

At each visit, address 1, 4, 2:

Recurrence symptoms to report immediately:

• New lumps or masses
• Persistent pain (bone, chest, abdominal, headaches)
• Unexplained weight loss
• Respiratory symptoms (dyspnea, persistent cough)
• Neurological changes
• Cancer-specific symptoms (bleeding, voice changes, swallowing difficulty for head/neck cancer)

Health promotion priorities:

• Smoking cessation (critical for all cancer survivors, especially lung and head/neck)
• Physical activity and weight management
• Dental care (especially head/neck cancer survivors)
• Age-appropriate screening for other cancers per general population guidelines

Genetic Counseling and High-Risk Screening 1

Refer for genetic counseling if:

• Strong family history of cancer (breast, colon, endometrial)
• Age ≤60 years with triple-negative breast cancer
• Ashkenazi Jewish heritage with breast/ovarian cancer
• Male breast cancer
• Bilateral breast cancer

High-risk patients may require intensified surveillance (e.g., breast MRI, colonoscopy at shorter intervals).

Care Coordination

Optimal transition model 8, 3:

• Oncology team leads surveillance initially with detailed treatment summary and follow-up plan provided to primary care
• Primary care can assume primary responsibility after approximately 1 year for early-stage disease with good prognosis
• Maintain clear communication channels for re-referral when concerning symptoms arise
• Patients receiving ongoing adjuvant endocrine therapy should maintain oncology involvement

Survivorship care plans should include 8:

• Cancer diagnosis and stage
• Treatment received (surgery, radiation, chemotherapy details)
• Expected late and long-term effects
• Specific surveillance schedule
• Contact information for oncology team
• Recommendations for health promotion

Performance Status Considerations 6

Surveillance imaging may not be offered to patients who are:

• Clinically unsuitable for further treatment due to comorbidities
• Unwilling to accept further treatment
• However, age alone should NOT preclude surveillance imaging

Quality of Life Focus

Remember that surveillance must balance early detection benefits against 8:

• Psychological burden of frequent testing and cancer-related anxiety
• Financial toxicity from imaging and visits
• Time burden and impact on daily life
• Risk of false-positive results leading to unnecessary interventions

The evidence consistently shows that symptom-directed evaluation combined with cancer-specific imaging protocols provides the best balance of early detection, cost-effectiveness, and quality of life preservation.